ClinicalTrials.gg
Not yet recruitingNCT07670065Updated Jun 26, 2026

Direct Angio Suite Acute Stroke Intervention With CT/DSA Hybrid Emergency Stroke Unit

A Phase 3 interventional study of Direct Angio Suite Acute Stroke Intervention With CT/DSA Hybrid Emergency Stroke Unit and Conventional Thrombectomy in Acute Ischemic Stroke and Large Vessel Occlusion, sponsored by Beijing Tiantan Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Beijing Tiantan Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 86 studies in Ischemic Stroke by Beijing Tiantan Hospital — 46 open to participants now, 47 under way, 15 of them phase 3. Ischemic Stroke · Beijing Tiantan Hospital.

Planned enrollment
58th of 77
232 · median 564
Started
2026
with 18 others
Phase 3
28 of 86
15 open now
Primary completion
2027-08
later than 27 of 46 live
Registered
81st of 86
by date

Among the 86 studies in Ischemic Stroke by Beijing Tiantan Hospital, this one is the 58th largest by planned enrollment of the 77 interventional ones that give a count, is one of 19 that started in 2026, is one of 28 in phase 3, reaches primary completion later than 27 of the 46 other live ones, and was the 81st registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

46 of the 86 studies in Ischemic Stroke by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

41 more — sign in →

By country, each count listing its studies:

All 46 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Ischemic Stroke by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

This study investigates whether direct transfer to an emergency stroke unit equipped with NeuAngio-CT reduces time to endovascular reperfusion in patients with acute ischemic stroke and suspected intracranial large-vessel occlusion.Those aged 18-60 years with acute ischemic stroke who are eligible for endovascular thrombectomy within 24 hours of symptom onset will be enrolled. Participants will be randomly assigned to one of two groups. In the intervention group, participants will undergo femoral or radial artery puncture, followed by intracranial and cervical CT angiography with intra-arterial contrast injection (iacCTA) performed using the sliding-rail NeuAngio-CT, and subsequent thrombectomy guided by fused CTA-DSA images. In the control group, participants will receive intracranial and cervical CT angiography with intra-venous contrast injection and the thrombectomy will guided by standard DSA imaging without use of the sliding-rail CT. The primary endpoint is puncture-to-successful-reperfusion time (PRT); if successful reperfusion is not achieved, the end-of-procedure time will be used.

Read the detailed description

Timely reperfusion is critical for acute ischemic stroke. Current workflows require participants to undergo intracranial and cervical CTA in a CT suite before transfer to the catheterization laboratory, which adds significant delays. Furthermore, conventional intracranial and cervical CTA has limited sensitivity for detecting medium vessel occlusions due to venous contamination and calcification artifacts. We established an emergency stroke unit with NeuAngio-CT, which is sited within the emergency department and integrates clinical assessment, brain imaging, and initial treatment for patients with suspected stroke. It optimizes the thrombectomy workflow by providing a onestop, multimodal diagnostic and therapeutic solution that eliminates patient transfers between CT and the angiography suite. The system enables rapid switching and integration between CT and digital subtraction angiography (DSA) with real-time acquisition and fusion of CT and DSA datasets, yielding more comprehensive and accurate imaging information to support treatment decisions.This is a multicenter, open-label, randomized, parallel-controlled, non-inferiority trial. Those aged 18-60 years with acute ischemic stroke who are eligible for endovascular thrombectomy within 24 hours of symptom onset will be enrolled. Participants must have completed a venous head and neck CTA confirming a treatable vessel occlusion. They will be randomly assigned in a 1:1 ratio to the experimental group or the control group.In the intervention group, participants will undergo femoral or radial artery puncture, followed by intracranial and cervical CT angiography with intra-arterial contrast injection (iacCTA) performed using the sliding-rail NeuAngio-CT, and subsequent thrombectomy guided by fused CTA-DSA images. In the control group, participants will receive intracranial and cervical CT angiography with intra-venous contrast injection and the thrombectomy will guided by standard DSA imaging without use of the sliding-rail CT. The primary endpoint is puncture-to-successful-reperfusion time (PRT); if successful reperfusion is not achieved, the end-of-procedure time will be used. Safety endpoints include total contrast agent volume, cumulative radiation dose, rate of serious surgical complications within 7 days or before discharge, and incidence of adverse events and serious adverse events. All participants will be assessed on the day of enrollment and at postoperative day 7 or hospital discharge.

03

Conditions studied

  • Acute Ischemic Stroke
  • Large Vessel Occlusion

Browse trials for

Keywords

  • Sliding CT/DSA
  • One-stop Management
  • Mechanical Thrombectomy
  • Emergency Stroke Care
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-60 years;
  2. Clinical diagnosis of acute ischemic stroke eligible for immediate endovascular treatment;
  3. Time from symptom onset or last known well ≤ 24 hours;
  4. Intravenous intracranial and cervical CT angiography completed;
  5. Confirmed target vessel occlusion amenable to endovascular intervention based on intravenous intracranial and cervical CT angiography findings;
  6. Written obtained from the patient or their legally authorized representative.

Exclusion criteria

Exclusion Criteria

  1. Known contrast agent allergy;
  2. Renal insufficiency with (glomerular filtration rate) \< 45 mL/min/1.73 m²;
  3. History of kidney transplantation;
  4. Concomitant diabetes mellitus with current use of metformin;
  5. Women who are pregnant, breastfeeding, or have a positive pregnancy test at admission;
  6. hypertension (defined as systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) (Note: patients may be enrolled if blood pressure is successfully reduced and maintained at an acceptable level with antihypertensive therapy);
  7. Intracranial space-occupying lesion or other conditions deemed unsuitable for endovascular intervention on imaging;
  8. Any other serious comorbidity or complication that may interfere with study conduct or evaluation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
232 participants (estimated)

Study arms

  • Experimental
    Direct Angio Suite Acute Stroke Intervention With CT/DSA Hybrid Emergency Stroke Unit

    Participants will undergo femoral or radial artery puncture, followed by intracranial and cervical CT angiography with intra-arterial contrast injection (iacCTA) performed using the sliding-rail NeuAngio-CT, and subsequent thrombectomy guided by fused CTA-DSA images.

    Device: Direct Angio Suite Acute Stroke Intervention With CT/DSA Hybrid Emergency Stroke Unit

  • Placebo comparator
    Conventional Thrombectomy

    Participants will receive intracranial and cervical CT angiography with intra-venous contrast injection and the thrombectomy will guided by standard DSA imaging without use of the sliding-rail CT.

    Device: Conventional Thrombectomy

Interventions

  • DeviceDirect Angio Suite Acute Stroke Intervention With CT/DSA Hybrid Emergency Stroke Unit

    Participants will undergo femoral or radial artery puncture, followed by intracranial and cervical CT angiography with intra-arterial contrast injection (iacCTA) performed using the sliding-rail NeuAngio-CT, and subsequent thrombectomy guided by fused CTA-DSA images.

  • DeviceConventional Thrombectomy

    Participants will receive intracranial and cervical CT angiography with intra-venous contrast injection and the thrombectomy will guided by standard DSA imaging without use of the sliding-rail CT.

06

What researchers measure

Primary outcomes

  1. Puncture-to-reperfusion time (PRT)

    Time from puncture completion to successful recanalization; if recanalization is not achieved, the end of procedure is used instead.

    Time frame: immediately after the intervention

Secondary outcomes

  1. Intervention-to-reperfusion time (IRT)

    Time frame: immediately after the intervention

  2. Procedure duration

    Time frame: immediately after the intervention

  3. Puncture completion-to-first-recanalization time

    Time frame: immediately after the intervention

  4. First-pass recanalization rate

    Time frame: immediately after the intervention

  5. Contrast volume from puncture to end of procedure

    Time frame: immediately after the intervention

  6. Radiation dose from puncture to end of procedure

    Time frame: immediately after the intervention

  7. Rate of serious procedural complications at 7 days post-procedure or prior to discharge

    Time frame: at 7 days or at discharge

  8. Adverse events (AEs) and serious adverse events (SAEs)

    Time frame: at 7 days or at discharge

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Aug 2027, 14 months later.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 14 months is below that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2026
First posted
Jun 26, 2026
StartEst.
Jun 8, 2026
Primary completionEst.
Aug 15, 2027
CompletionEst.
Oct 15, 2027
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07670065
Responsible party
Yongjun Wang (Principal Investigator, Beijing Tiantan Hospital) — Principal investigator
First posted
Jun 26, 2026
Start date
Jun 8, 2026 (estimated)
Primary completion
Aug 15, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Jun 26, 2026

Study contacts

Yongjun Wang, Dr.
Contact
yongjunwang@ncrcnd.org.cn
59978555
Xuewei Xie, Dr.
Contact
xueweixie@163.com
59978555
Zeguang Ren, Dr.
study director · Beijing Tiantan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion